Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692.
Yale School of Medicine, New Haven, CT silvio.inzucchi@yale.edu.
Silvio E
SE
Inzucchi
Yale School of Medicine, New Haven, CT.
Catherine M
0000-0003-1254-6636
CM
Viscoli
Yale School of Medicine, New Haven, CT.
Lawrence H
LH
Young
Alpert Medical School of Brown University, Providence, RI.
Karen L
KL
Furie
Vermont College of Medicine, Burlington, VT.
Mark
M
Gorman
Yale School of Medicine, New Haven, CT.
Anne M
AM
Lovejoy
University of Tennessee Health Science Center, Memphis, TN.
Samuel
S
Dagogo-Jack
Case Western Reserve University and VA Medical Center, Cleveland, OH.
Faramarz
F
Ismail-Beigi
University of Pittsburgh School of Medicine, Pittsburgh, PA.
Mary T
MT
Korytkowski
Florida Hospital, Orlando, FL.
Richard E
RE
Pratley
VA Medical Center and University of Colorado School of Medicine, Denver, CO.
Gregory G
GG
Schwartz
Yale School of Medicine, New Haven, CT.
Walter N
WN
Kernan
D002561:Cerebrovascular Disorders; D003924:Diabetes Mellitus, Type 2; D006801:Humans; D006943:Hyperglycemia; D007004:Hypoglycemic Agents; D007328:Insulin; D007333:Insulin Resistance; D000077205:Pioglitazone; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077205:Pioglitazone